

ORIGINAL RESEARCH

Thirty-Day Mortality Risk Associated With the Postoperative Nonresumption of Angiotensin-Converting Enzyme Inhibitors: A Retrospective Study of the Veterans Affairs Healthcare System

Seshadri C. Mudumbai, MD, MS^{1*}, Steven Takemoto, PhD², Brian A. Cason, MD², Selwyn Au, MS³, Anjali Upadhyay, MS⁴, Arthur W. Wallace, MD, PhD²

¹Anesthesia Service, Veterans Affairs Palo Alto Health Care System, Palo Alto and Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, California; ²Anesthesia Service, Veterans Affairs Medical Center, San Francisco, and Department of Anesthesiology and Perioperative Care, University of California, San Francisco, California; ³Cooperative Studies Program Coordinating Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California; ⁴Health Economics Resource Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACE-Is) are a widely used class of cardiovascular medication. However, limited data exist on the risks of postoperative nonresumption of an ACE-I.

OBJECTIVE: To evaluate the factors and 30-day mortality risks associated with the postoperative nonresumption of an ACE-I.

DESIGN: A retrospective cohort study.

SETTING: Veterans Affairs (VA) Healthcare System.

PATIENTS: A total of 294,505 admissions in 240,978 patients with multiple preoperative prescription refills (>3) for an ACE-I who underwent inpatient surgery from calendar years 1999 to 2012.

INTERVENTION: None.

MEASUREMENTS: We classified surgical admissions based upon the timing of postoperative resumption of an ACE-I prescription from the day of surgery through postoperative days 0 to 14 and 15 to 30, and collected 30-day

mortality data. We evaluated the relationship between 30-day mortality and the nonresumption of an ACE-I from postoperative day 0 to 14 using proportional hazard regression models, adjusting for patient- and hospital-level risk factors. Sensitivity analyses were conducted using more homogeneous subpopulations and propensity score models.

RESULTS: Twenty-five percent of our cohort did not resume an ACE-I during the 14 days following surgery. Nonresumption of an ACE-I within postoperative day 0 to 14 was independently associated with increased 30-day mortality (hazard ratio: 3.44; 95% confidence interval: 3.30-3.60; $P < 0.001$) compared to the restart group. Sensitivity analyses maintained this relationship.

CONCLUSIONS: Nonresumption of an ACE-I is common after major inpatient surgery in the large VA Health Care System. Restarting of an ACE-I within postoperative day 0 to 14 is, however, associated with decreased 30-day mortality. Careful attention to the issue of timely reinstatement of chronic medications such as an ACE-I is indicated. *Journal of Hospital Medicine* 2014;9:289-296. 2014 Society of Hospital Medicine

Perioperative medication management requires careful consideration, because surgical patients, especially older ones, may be receiving multiple medications for the treatment of acute or chronic comorbidities.¹ Because patients often present to surgery stabilized on their drug regimens, nonresumption of medications for chronic conditions may be problematic in controlling underlying diseases.² For example, nonresumption of cardiovascular medications such as β -blockers postoperatively has been shown to lead to increased longer-term mortality.³ Little

data, however, exist to guide practitioners on the postoperative management risks for another widely used class of cardiovascular medication: angiotensin-converting enzyme inhibitors (ACE-Is).⁴

About 170 million prescriptions for an ACE-I are dispensed in the United States annually, which reflects a multiple criteria for their use including hypertension, heart failure, ischemic heart disease, coronary disease risk, diabetes mellitus, chronic kidney disease, recurrent stroke prevention, and vascular disease.⁵⁻⁷ ACE-Is have been shown to improve outcomes in patients with ischemic heart disease and heart failure.^{8,9} An observational study found that perioperative use of an ACE-I in coronary artery bypass grafting (CABG) patients was associated with increased mortality, use of vasopressors, and postoperative acute renal failure.¹⁰ Data also indicate that patients who continue the use of an ACE-I perioperatively can experience severe hypotension.¹¹ As a result, some have recommended that consideration be given to not restarting the ACE-I perioperatively, especially with hypertensive patients undergoing noncardiac surgery.¹² However, little evidence exists to document benefits and

*Address for correspondence and reprint requests: Seshadri Mudumbai, MD, Anesthesia Service 112A, VA Palo Alto Health Care System, 3801 Miranda Ave., Palo Alto, CA 94304; Telephone: 650-493-5000; Fax: 650-852-3243; E-mail: mudumbai@stanford.edu

*Published 2014. This article is a US Government work and, as such, is in the public domain of the United States of America.

Additional Supporting Information may be found in the online version of this article.

Received: April 16, 2013; Revised: February 4, 2014;

Accepted: February 13, 2014

2014 Society of Hospital Medicine DOI 10.1002/jhm.2182

Published online in Wiley Online Library (Wileyonlinelibrary.com).




FIG. 1. Selection of patients. Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor.

risks of not restarting an ACE-I in surgical patients for various intervals. To evaluate these risks, we tested the hypothesis that postoperative nonresumption of an ACE-I occurs frequently for broad cohorts of Veterans Affairs (VA) surgery patients within the first 14 days and is associated with increased 30-day mortality.

MATERIALS AND METHODS

After institutional review board approval (University of California, San Francisco), we examined surgeries conducted at hospitals at 120 stations within the VA Health Care System (VAHCS). The VAHCS is the largest integrated healthcare system in the United States, with long-standing electronic medical records capturing detailed demographic, pharmacy, and mortality information.¹³ Data were extracted from Medical Statistical Analysis System (SAS)[®] and Corporate Data Warehouse (CDW) files in the VA Informatics and Computing Infrastructure.¹⁴

Development of the Study Population

To identify surgery patients who were consistently prescribed an ACE-I preoperatively (Figure 1), we first

located 1,213,086 surgical admissions in 846,454 patients from 1999 to 2012 using Medical SAS files and classified them by specialty of the surgeon (eg, neurosurgery, orthopedic, urology, cardiothoracic, general, vascular, plastic, and other [such as gynecology]). We identified comorbidities and cardiovascular risk factors from inpatient/outpatient diagnosis files in the CDW using International Classification of Diseases (ICD-9) diagnosis codes (see Supporting Information, Tables 1 and 2, in the online version of this article). To ensure chronic preoperative ACE-I use, we included surgeries with ≥ 3 outpatient prescription fills of an ACE-I and < 180 -day gap. ACE-Is included benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, and ramipril. We excluded cases with a surgery in the prior 90 days and missing diagnosis codes. Our final population was comprised of 294,505 surgical admissions in 240,978 patients.

Postoperative Medication Use

We defined patients as postoperative “restart (0–14 days)” if an ACE-I was administered in-hospital (oral

TABLE 1. Demographics and Risk Factors of the Study Sample Stratified by Mortality at 30 Days

Parameter	Surgeries, No. (%), Total = 294,505	Died by 30-Days, Total = 9,227	P Value
No restart, 0–14 days*	59,949 (20%)	7.3%	<0.001
Restart, 0–14 days†	220,317 (75%)	2.1%	
Restart, 15–30 days‡	14,239 (5%)	1.7%	
Age, y			
<60	74,326 (14%)	1.7%	<0.001
61–70	97,731 (24%)	2.3%	
71–90	119,775 (60%)	4.6%	
>90	2,673 (1%)	6.9%	
Gender			
Female	7,186 (2%)	1.6%	<0.001
Male	287,319 (98%)	3.2%	
Indications for use of ACE-I§			
Hypertension	270,486 (92%)	2.8%	<0.001
Ischemic heart disease	129,212 (44%)	3.8%	<0.001
Vascular disease	75,410 (26%)	3.7%	<0.001
Heart failure	59,809 (20%)	5.7%	<0.001
Chronic kidney disease	8,804 (3%)	4.9%	<0.001
Diabetes mellitus	170,320 (58%)	3.0%	<0.001
Coronary disease risk¶	280,958 (95%)	3.1%	<0.001
Stroke	22,285 (8%)	5.2%	<0.001
Comorbidity score			
0	72,126 (24%)	1.4%	<0.001
1	59,609 (20%)	1.5%	
2–4	116,914 (40%)	3.5%	
>4	45,856 (16%)	7.0%	
Preoperative ACE-I gap, days			
0–45	21,383 (7%)	3.7%	<0.001
46–90	30,237 (10%)	3.8%	
91–180	242,885 (83%)	3.0%	
Surgical specialty			
General	98,210 (33%)	4.6%	<0.001
Neurosurgery	15,423 (5%)	2.3%	
Orthopedic	51,600 (18%)	1.9%	
Plastic	12,547 (4%)	3.8%	
Thoracic	44,728 (15%)	3.2%	
Urology	34,595 (12%)	1.5%	
Vascular	34,228 (12%)	2.8%	
Other (gynecology)	3,174 (1%)	1.4%	
Year of surgery			
1999–2002	66,689 (23%)	4.2%	<0.001
2003–2005	75,420 (26%)	3.4%	
2006–2008	76,563 (26%)	2.8%	
2009–2012	75,833 (26%)	2.2%	
No. of prior surgeries			
0	215,443 (74%)	3.2%	0.413
1	56,419 (19%)	3.1%	
≥2	22,643 (7%)	3.1%	
Length of stay, d			
1	40,538 (14%)	1.4%	<0.001
2–3	59,817 (20%)	1.4%	
4–7	83,366 (28%)	2.0%	
8–21	83,379 (28%)	4.7%	
>21	27,405 (9%)	8.0%	
Center surgical volume quartile**			
0%–25%	74,846 (25%)	3.7%	<0.001
25%–50%	74,569 (25%)	3.1%	
50%–75%	69,947 (24%)	2.8%	
75%–100%	75,143 (26%)	2.8%	
Center restart quartile††			
0%–25%	73,750 (25%)	3.1%	0.014
25%–50%	81,071 (28%)	3.0%	
50%–75%	83,952 (29%)	3.3%	
75%–100%	55,732 (19%)	3.2%	

TABLE 1. Continued

Parameter	Surgeries, No. (%), Total = 294,505	Died by 30-Days, Total = 9,227	P Value
No complication	80,700 (27%)	1.3%	<0.001
Minor complication‡‡	181,924 (62%)	4.2%	<0.001
Major complication§§	46,977 (16%)	8.3%	<0.001
Complications			
Arrhythmia	3,037 (1%)	2.0%	<0.001
Bleeding	12,887 (4%)	4.8%	<0.001
Deep venous thrombosis	6,075 (2%)	3.6%	<0.001
Myocardial infarction	9,114 (3%)	7.7%	<0.001
Pneumonia	109,660 (37%)	5.1%	<0.001
Pulmonary embolism	5,064 (2%)	6.2%	<0.001
Renal failure	25,513 (9%)	11.0%	<0.001
Sepsis	5,846 (2%)	16.5%	<0.001
Stroke	19,546 (7%)	5.0%	<0.001
Urinary tract infection	32,548 (11%)	4.9%	<0.001

NOTE: Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor

*No restart (0–14 days) = no ACE-I from postoperative day 0 to 14.

†Restart (0–14 days) = angiotensin converting enzyme inhibitors (ACE-I) restarted from postoperative day 0 to 14.

‡Restart (15–30 days) = ACE-I restarted from postoperative day 15 to 30. §Patients may have more than 1 potential indication for use of an ACE-I.

¶Coronary disease risk is defined as the presence of 2 or more of the following heart disease risk factors: acute myocardial infarction, cardiovascular disease, chronic heart failure, hypertension, hyperlipidemia, diabetes with or without complications, smoking, age >60 years.

||Comorbidities were aggregated using an approach reported by Gagne et al. that combines the Charlson and Elixhauser measures.

||Preoperative ACE-I gap was defined as the number of days without a fill of an ACE-I prescription.

**Center surgical volume quartiles were defined using the total number of surgeries done at a hospital for the study period (1999–2012).

††Center restart quartiles were defined using the total number of surgery patients who were restarted on their ACE-I by 14 days at a hospital for the study period.

‡‡Minor complications were based on the presence of 1 or more of the following complications: arrhythmia, postoperative bleeding, deep venous thrombosis, pneumonia, pulmonary embolism, sepsis, and urinary tract infection.

§§Major complications were based on the presence of 1 or more of the following complications: myocardial infarction, renal failure, and stroke.

or intravenous) or a postdischarge outpatient ACE-I prescription was filled in the 14 days following surgery. In absence of ACE-I administration or prescription during postoperative days 0 to 14, patients were classified as “no restart (0–14 days).” Intraclass changes from one ACE-I to another were considered a restart if they occurred within 0 to 14 days of surgery. We also tracked ACE-I prescription fills through postoperative day 15 to 30 (ie, restart [15–30 days]) and noted administration or filling of oral medications. Oral medications were classified as tablets or caplets in formularies.

Patient Characteristics

We categorized patients by age strata: <60, 61 to 70, 71 to 90, and >90 years old; gender; and epochs (every 3–4 years starting from calendar year 1999). We tracked prior surgery admissions and length of stay.

Hospital Factors

To account for clustering of surgeries and hospital-related factors affecting ACE-I use practices, we

TABLE 2. Risk of 30-day Mortality Associated With No Restart vs Restart of an ACE-I

Unadjusted Hazard for 30-Day Mortality (OR [95% CI])			Adjusted hazard for 30 day mortality (OR [95% CI])		
Restart (0–14 Days) (Referent)*	No Restart, 0–14 Days [†]	Restart, 15–30 Days [‡]	Restart, 0–14 Days (Referent)	No Restart, 0–14 Days	Restart, 15–30 Days
1	3.44 (3.30–3.60) [§]	0.23 (0.20–0.26) [§]	1	2.79 (2.67–2.92) [§]	0.24 (0.21–0.28) [§]
Restart, 0–14 Days (Referent)	No Restart, 0–14 Days	NA	Restart, 0–14 Days (Referent)	No Restart, 0–14 Days	NA
1	2.92 (2.80–3.05) [§]	NA [¶]	1	2.39 (2.29–2.50) [§]	NA [¶]

NOTE: Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; CI, confidence interval, NA, nonapplicable; OR, odds ratio.

*Restart (0–14 days) = ACE-I restarted from postoperative day 0 to 14.

[†]No restart (0–14 days) = no ACE-I from postoperative day 0 to 14.

[‡]Restart (15–30 days) = ACE-I restarted from postoperative day 15 to 30.

[§]All *P* values were statistically significant (*P* < 0.001).

[¶]Restart day 15–30 was not included in this model.

divided hospitals into quartiles of (1) total surgical volume based on total number of surgeries done at a hospital from 1999 to 2012 (0%–25%, *n* < 2378; 50%, *n* = 3498; 75%, *n* = 4531; highest surgical volume, 8162); and (2) percent of cases restarted on ACE-I at 14 days (71%, 76%, 79%, and 100%).

Indications, Patient Illness Severity, and Complications

We determined probable indications for ACE-I usage (ie, heart failure) and comorbidities using ICD-9 codes in medical records prior to surgical admissions (see Supporting Information, Tables 1 and 2, in the online version of this article). Comorbidities were aggregated using algorithms developed by Gagne aggregating comorbidity conditions (defined by Elixhauser) into scores similar to Charlson scores.¹⁵ The Gagne score has higher correlation with 30-day, 90-day, 180-day, and 1-year mortality than Charlson scores.¹⁵

After evaluating secondary diagnosis codes in the clinic or hospital visits prior to surgery date, complications were defined using codes newly incident after surgery and up to 90 days following discharge. We organized complications into “major” and “minor.” Major complications were myocardial infarction, renal failure, and stroke; minor complications included arrhythmia, postoperative bleeding, deep venous thrombosis, pneumonia, pulmonary embolism, sepsis, and urinary tract infection.

Mortality

Deaths were ascertained from VA Vital Status files.

Statistical Analysis

The unit of analysis was surgical episode; surgeries were stratified by 30-day mortality. We evaluated differences between the 2 groups using χ^2 tests accounting for restarting of an ACE-I through day 30, risk factors, patient, and hospital-stay characteristics. We also compared those who did not restart from postoperative day 0 to 14 and 15 to 30 to all others who did not restart at any point up to 90 days. Independent variables included age, gender, indications for ACE-I, comorbidity burden, type and year of surgery, previ-

ous hospitalizations, length of stay, and complications. To account for site-related effects and clustering of observations (ie, surgeries within hospitals), we included quartiles of hospital volume and hospital rates of ACE-I restart in models and used cluster command in Stata (StataCorp, College Station, TX).

Risk of Mortality

We developed Cox regression models to examine 30-day mortality risks between restart (0–15 days) and restart (15–30 days) groups to a reference group of patients who did not restart in the first 14 days after surgery (ie, no restart [0–14 days]). We considered those who had restarted their ACE-I beyond day 14 and excluded these from comparisons to the no restart group. Independent variables included age, gender, indications for ACE-I usage, comorbidity, type and year of surgery, previous hospitalizations, length of stay, quartiles of hospital surgical volume and rates of restarting an ACE-I, and complications.

Sensitivity Analyses

Using Cox regression, we tested robustness of results regarding no restart (0–14 days) versus restart (0–14 days) in subsets after excluding patients who died postoperative day 0 to 2 and those with no oral medications on postoperative day 0 to 14, those with low comorbidity burden, within subtypes of surgery, and by surgical episode. To evaluate confounding by indication, we examined subsets without major complications and after excluding patients who died postoperative day 0 to 14. We then developed a propensity score model using quintiles to estimate average treatment effects associated with no restart (0–14 days).¹⁶ A propensity score reflecting the probability of ACE-I administration at 14 days was developed using logistic regression accounting for all independent variables. For analyses, we considered a 2-tailed *P* value of ≤ 0.05 as statistically significant. Stata 12.1 software (Stata Corp.) was used.

RESULTS

Table 1 describes the characteristics and 30-day mortality rates for our cohort. By postoperative day 14,

TABLE 3. Sensitivity Analyses: Risk of 30-Day Mortality Associated With ACE-I No Restart (0–14 Days)

Population	Unadjusted Hazard Ratio (95% CI)*	Adjusted Hazard Ratio (95% CI)*
Exclude patients who died day 0–2 or no record of oral medications days 0–14	2.29 (2.18–2.40)	1.88 (1.79–1.98)
Cases with 0–2 comorbidity score [†]	1.92 (1.74–2.12)	1.72 (1.55–1.90)
Only cardiothoracic surgery cases [†]	2.07 (1.83–2.35)	1.94 (1.70–2.21)
Only neurosurgery cases [†]	1.49 (1.10–2.02)	1.46 (1.07–2.00)
Only orthopedic surgery cases [†]	2.48 (2.12–2.91)	2.17 (1.84–2.55)
Only urologic surgery cases [†]	1.92 (1.58–2.34)	1.37 (1.12–1.68)
Only first surgery cases [†]	2.22 (2.09–2.35)	1.86 (1.75–1.97)
Subsequent surgery cases [†]	2.49 (2.27–2.73)	1.96 (1.78–2.16)
Cases with no major complications [†]	2.49 (2.36–2.64)	2.25 (2.12–2.38)
Exclude patients who died within the first 14 days after surgery [‡]	2.26 (2.11–2.41)	1.66 (1.55–1.78)

NOTE: All analyses are for 30-day mortality for no restart (0–14 days) (ie, no ACE-I from postoperative day 0 to 14). The reference group was restart (0–14 days) (ie, ACE-I restarted on postoperative day 0 to 14). All subpopulations were developed excluding patients who were unable to take oral medications. Sensitivity analyses used Cox regression and included all independent variables from the main model unless not indicated by population definition: age, gender, comorbidity score, indications for ACE-I use, type and year of surgery, previous hospitalizations, length of stay, quartiles of hospital volume, quartiles of hospital rates of ACE-I restart, and complications.

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; CI, confidence interval.

*The *P* values for all unadjusted and adjusted hazard ratios were statistically significant ($P < 0.001$).

[†]Excluding those who died on day 0 to 2 or had no record of oral medications days 0 to 14.

[‡]Excluding those who had no record of oral medications days 0 to 14.

75% of the study sample ($n = 220,317$) had restarted an ACE-I (Figure 1). Our sample consisted primarily of older men with a substantial comorbidity burden and multiple indications for an ACE-I. Most patients had 1 surgical episode, with the largest fraction undergoing general surgery overall. A third of the cases had lengths of stay >1 week, and surgeries occurred throughout the study period. The largest number of surgeries was noted for centers in 75% to 100% surgical volume and 50% to 75% restart quartiles. Most surgeries had no or minor complications.

The no restart (0–14 days) group had a higher 30-day mortality rate (7.3%) compared to those who restarted by postoperative day 14 (2.1%) or 30 (1.7%). The highest mortality rates were found in patients aged >90 years, with a >4 comorbidity index or hospital stays >3 weeks, and those experiencing major postoperative complications.

30-Day Mortality

Table 2 indicates that nonresumption of an ACE-I from postoperative day 0 to 14 was independently associated with an approximately 2.5-fold increased risk of 30-day mortality (hazard ratio [HR]: 3.44; 95% confidence interval [CI]: 3.30–3.60; $P < 0.001$). Lower hazard ratios were noted when patients who restarted postoperative days 15 to 30 were included in models (HR: 2.79; 95% CI: 2.67–2.92; $P < 0.001$).

The sensitivity analyses illustrate the durability of treatment effects (Table 3). After excluding patients who died during days 0 to 2 and without a record of receiving an oral medication by postoperative day 14, ACE-I nonresumption was associated with an 88% increase in 30-day mortality risk (HR: 1.88; 95% CI: 1.79–1.98; $P < 0.001$). Similar increased risks were seen in patients with less comorbidity for each specialty and for those who did not experience a major

complication. In data not shown, adjusting by propensity score did not modulate treatment effects (HR for no restart [0–14 days]: 3.03; 95% CI: 2.78–3.30; $P < 0.001$).

Other factors associated with increased 30-day mortality are displayed in Table 4. The risk associated with not restarting an ACE-I was similar to effect of age >90 years and a >4 comorbidity index.

DISCUSSION

The results from this national retrospective study confirm our hypothesis that nonresumption of an ACE-I for 14 or more postoperative days occurs frequently for VA surgery patients. However, we found that nonresumption of an ACE-I during the first 2 weeks after surgery is independently associated with increased 30-day mortality. Our study is one of the first to examine the patterns and risks of postoperative ACE-I management across a large and varied surgical population.^{11,17}

The lack of inpatient and outpatient ACE-I prescription use by postoperative day 14 across multiple surgery classes suggests that surgical patients may be prone to short-term nonresumption of an ACE-I. Our intention in using a 14-day window to evaluate restarting strategies was to account for immediate postoperative management. After surgery, careful appraisal of whether medications should be restarted is often necessary in the face of substantially deranged physiology, hypercoagulability, and blood loss.¹⁸ After physiologic stabilization over several days, cardiovascular drugs are usually restarted thereafter to help manage chronic comorbidities.¹⁹ One immediate conclusion from our findings is that ACE-I are commonly discontinued perioperatively (potentially due to concerns for hypotension), and are often not restarted.^{20–25}

Our rates of ACE-I nonresumption are comparable to rates of nonresumption reported postoperatively for

TABLE 4. Factors Associated With Increased 30-Day Mortality

Parameter	Reference Group	Unadjusted Hazard Ratio (95% CI)*	Adjusted Hazard Ratio (95% CI)*
No restart (0–14 days) [†]	Restart (0–14 days) [‡]	2.92 (2.80–3.05)	2.39 (2.29–2.50)
Age, y			
61–70	Age <60 years	1.33 (1.24–1.43)	1.36 (1.26–1.46)
71–90		2.72 (2.55–2.90)	2.01 (1.89–2.30)
>90		4.05 (3.45–4.76)	2.70 (2.18–3.74)
Male	Female	2.11 (1.74–2.57)	1.54 (1.27–1.88)
Comorbidity score			
2–4	1	2.19 (2.06–2.33)	1.36 (1.27–1.45)
>4		4.57 (4.29–4.87)	1.97 (1.82–2.13)
Center surgical volume quartile			
0–25th percentile	76th–100th percentile	1.35 (1.28–1.43)	1.21 (1.14–1.29)
26th–50th percentile		1.11 (1.04–1.18)	1.05 (0.99–1.12)
Indications			
Heart failure	No heart failure	2.23 (2.14–2.34)	1.19 (1.12–1.26)
Year of surgery			
1999–2002	2006–2008	1.49 (1.41–1.58)	1.07 (1.01–1.13)
2003–2005		1.21 (1.45–1.29)	1.13 (1.06–1.20)

NOTE: Analysis is for 30-day mortality for no restart (no ACE-I postoperative day 0–14). The reference group was restart (0–14 days) (ie, ACE-I restarted on postoperative day 0–14). Cox regression included all independent variables: age, gender, comorbidity score, indications for ACE-I use, type and year of surgery, previous hospitalizations, length of stay, quartiles of hospital volume, quartiles of hospital rates of ACE-I restart, and complications.

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; CI, confidence interval.

*All *P* values were statistically significant (*P* < 0.001).

[†]No restart (0–14 days): ACE-I postoperative day 0–14.

[‡]Restart (0–14 days): ACE-I restarted on postoperative day 0 to 14.

other medications and raise concerns for inadequate medication reconciliation in surgical cohorts. Bell et al. conducted a population-based cohort study of patients undergoing elective surgery and found that 11.4% of 45,220 patients chronically prescribed warfarin were not restarted by postoperative day 180.²² A subsequent study showed intensive care unit (ICU) admission was associated with increased rates of not restarting 4 of 5 medication groups (range, 4.5%–19.4%; statins, antiplatelet/anticoagulant agents, levothyroxine, respiratory inhalers, and gastric acid-suppressing drugs).²¹ One-year follow-up showed elevated odds for the secondary composite outcome of death in the statins group (odds ratio [OR]: 1.07; 95% CI: 1.03–1.11) and antiplatelet/anticoagulant agents group (OR: 1.10; 95% CI: 1.03–1.16). Drenger et al. noted a 50% rate for no restart of ACE-I after CABG surgery; restarting was associated with a decreased composite outcome of cardiac, cerebral, and renal events and in-hospital mortality (OR: 0.50; 95% CI: 0.38–0.66).²⁶ Because medication management has been noted to be problematic at care transitions, the inpatient medication reconciliation recommendations articulated in recent Joint Commission National Patient Safety Goals may be particularly relevant for high-risk surgical patients who experience multiple transitions of care (ie, operating room to ICU to surgical ward to rehabilitation unit to discharge).^{19,24,27}

In examining the crucial interval for the surgical patient—the postoperative period when medication changes are common—we found a nearly 2.5-fold

increase in risk for 30-day mortality associated with nonresumption of an ACE-I.^{4,19,28} We also noted that those who were restarted later on day 15 to 30 fared better than those not restarted (Table 2). Similar effect sizes have been found with postoperative nonresumption of other cardiovascular medications. Not restarting chronic β -blocker treatment after surgery is associated with a significant 1-year mortality risk (HR: 2.7; 95% CI: 1.2–5.9).²⁹ Postoperative statin withdrawal (>4 days) is an independent predictor of postoperative myonecrosis (OR: 2.9; 95% CI: 1.6–5.5).^{30,31} Biologic mechanisms contributing to mortality after a temporary failure to restart an ACE-I are speculative and were not addressed in this study. Potential mechanisms may lie with hypertensive rebound and associated cardiac decompensation. Withdrawing an ACE-I can cause rapid increases in blood pressure within 48 hours on home self-measured blood pressure in hypertensive patients and in diabetic patients with chronic renal failure.^{32,33} Patients with heart failure or coronary artery disease may then experience myocardial ischemia in the context of elevated blood pressure. Not restarting an ACE-I may also lead to compromised microcirculatory flow with renal complications and mortality.^{34,35}

Alternative explanations for the magnitude of our findings may lie with unmeasured confounders. Our analysis did not evaluate potential interactions arising from the failure to restart of all other medications (eg, β -blockers) or evaluate changes to angiotensin receptor blockers (ARBs). In addition, our study lacked

data on health system variations or emergent versus elective surgeries. However, a key starting point of our analysis was distinguishing between purposeful versus potentially unintentional nonresumption of an ACE-I. To accomplish this, we included patients who had at least 3 prescription ACE-I fills prior to surgery, evaluated the preoperative indications for an ACE-I and the ability to take postoperative oral medications (eg, immortal time bias), and accounted for minor and major postoperative complications.

To address bias from unmeasured confounders, we conducted sensitivity analyses in more homogeneous subpopulations. With each sensitivity analysis, we found consistently strong associations between increased 30-day mortality and nonresumption of an ACE-I (Table 3). Strong effects were observed in patients without major complications and with low comorbidity burdens, patients in whom we would not expect an effect. Because deaths in postoperative day 0 to 2 could be attributed to surgical factors (ie, hemorrhage) or that patients who did not restart an ACE-I in postoperative day 0 to 14 were too sick to tolerate oral medications, we excluded these patients along with patients who died before postoperative day 14. Both sensitivity analyses maintained our primary finding. Somewhat attenuated risks were found when we examined ACE-I nonresumption by individual surgery types, perhaps reflective of differences in comorbidity burden.

Finally, although this study did not examine predictors of nonresumption, our models showed that in the context of postoperative ACE-I management, factors including increasing age, being male, those with heart failure, and surgeries conducted in centers with low surgical volume were associated with increased 30-day mortality (Table 4). Future research might consider how reinstatement of an ACE-I occurs in these subpopulations to identify potential mechanisms for nonresumption.

Our study has several strengths. We examined patients over a decade, considered all major types of surgery, and studied patients across a healthcare system. Moreover, we used computerized prescription data and medical records (eg, discharge diagnosis, ICD-9 codes) to derive risk factors. VA prescription data are standardized and accurate because of intensive efforts to contain costs.³⁶ Within VA data, the estimated sensitivity of computerized diagnoses exceeds 80% in the administrative files, with specificity of 91% to 100% for common diagnoses such as coronary artery disease.³⁷ These records also carefully and accurately identify death.³⁸

We also identified potential limitations to our study. First, a retrospective, observational, cohort study may be prone to selection bias, and therefore we report associations that are not necessarily causal relationships. However, our methods are supported by the fact that we developed a large study sample consisting of consecutive surgical patients over a decade and

noted large effect sizes across multiple subpopulations. Second, for group assignment, we used prescription records rather than medication administration data. Nevertheless, a cohort analysis focusing on exposure is standard for epidemiologic studies and shows outcomes of care resulting from daily clinical practice.³⁹ Third, we did not study the cause of death, data that may help to identify potential causal pathways between not restarting an ACE-I and mortality. Fourth, our results come from VA medical centers and so may not be generalizable to non-VA institutions. However, the length of observation under conditions of routine clinical practice at multiple medical centers and a diverse set of surgical procedures support the external validity of our study results. Fifth, we did not have clinical data accounting for surgeon-level effects potentially affecting rates of nonresumption of an ACE-I, American Society of Anesthesiology physical status, information on perioperative hypotension or vasopressors, or the presence of a postoperative primary care visit.

In conclusion, in the VA Healthcare System, temporary nonresumption of an ACE-I is common. Postoperative nonresumption of an ACE-I, although sometimes indicated and appropriate, is associated with increased risk of mortality. Careful attention to the issue of eventual reinstatement of medications for chronic conditions, such as an ACE-I, is indicated to avoid unnecessary mortality. Because early experience showed that dose titration was a key for successful application of an ACE-I, practitioners may also need to consider dose modification rather than simply continuation or not restarting.⁴⁰ Future research is needed to confirm our results in other healthcare systems and to define mechanisms that link postoperative nonresumption of an ACE-I to mortality.

Acknowledgements

The authors acknowledge Dr. Edward R. Mariano, Chief Anesthesia Service, VA Palo Alto Health Care System, and Associate Professor, Stanford Department of Anesthesiology for general support of this research and critical review of the manuscript. We would also like to thank Dr. Ronald Pearl, Chair, Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, for his support of our research. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Center, San Francisco and Veterans Affairs Palo Alto Healthcare System.

Disclosure: The Northern California Institute for Research and Education and the Veterans Affairs Medical Center, San Francisco, California supported this work. This work was presented at the American Society of Anesthesiologists Annual Meeting, Chicago, Illinois, October 15–19, 2011, and the Veterans Affairs National Health Services Research and Development National Conference, National Harbor, Maryland, July 16–19, 2012.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

References

1. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. *Fam Pract*. 2000;17(3):261–267.
2. Kennedy JM, van Rij AM, Spears GF, Pettigrew RA, Tucker IG. Polypharmacy in a general surgical unit and consequences of drug withdrawal. *Br J Clin Pharmacol*. 2000;49(4):353–362.

3. Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. *Am Heart J*. 2001;141(1):148–153.
4. Whinney C. Perioperative medication management: general principles and practical applications. *Cleve Clin J Med*. 2009;76(suppl 4):S126–S132.
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560–2572.
6. IMS Health. Top therapeutic classes by U.S. dispensed prescriptions. April 7, 2011. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/2010_Top_Therapeutic_Classes_by_RX.pdf. Accessed September 5, 2011.
7. Brugs JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. *Eur Heart J*. 2009;30(11):1385–1394.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *The Heart Outcomes Prevention Evaluation Study Investigators*. *N Engl J Med*. 2000;342(3):145–153.
9. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med*. 1992;327(10):678–684.
10. Miceli A, Capoun R, Fino C, et al. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. *J Am Coll Cardiol*. 2009;54(19):1778–1784.
11. Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. *Anesth Analg*. 2005;100(3):636–644.
12. Poldermans D, Bax JJ, Boersma E. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). *Eur Heart J*. 2009;30(22):2769–2812.
13. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. *N Engl J Med*. 2003;348(22):2218–2227.
14. VA Information Resource Center; VIREC Research User Guide: VHA Decision support system clinical national data extracts. 2nd ed. Hines, IL: U.S. Department of VA, Health Services Research and Development Service, VA Information Resource Center, 2009. Available at: <http://www.virec.research.va.gov/RUGs/RUGs-Index.htm>. Accessed February 27, 2013.
15. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. *J Clin Epidemiol*. 2011;64(7):749–759.
16. Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. *Multi Behav Res*. 2011;46(1):119–151.
17. Cygan R, Waitzkin H. Stopping and restarting medications in the perioperative period. *J Gen Intern Med*. 1987;2(4):270–283.
18. Smith MS, Muir H, Hall R. Perioperative management of drug therapy, clinical considerations. *Drugs*. 1996;51(2):238–259.
19. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation*. 2007;116(17):1971–1996.
20. Pippins JR, Gandhi TK, Hamann C, et al. Classifying and predicting errors of inpatient medication reconciliation. *J Gen Intern Med*. 2008;23(9):1414–1422.
21. Bell CM, Brener SS, Gunraj N, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA*. 2011;306(8):840–847.
22. Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, Urbach DR. Potentially unintended discontinuation of long-term medication use after elective surgical procedures. *Arch Intern Med*. 2006;166(22):2525–2531.
23. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. *J Hosp Med*. 2007;2(5):314–323.
24. Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. *Am J Health Syst Pharm*. 2004;61(9):899–912.
25. Rosenman DJ, McDonald FS, Ebbert JO, Erwin PJ, LaBella M, Montori VM. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. *J Hosp Med*. 2008;3(4):319–325.
26. Drenger B, Fontes ML, Miao Y, et al. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. *Circulation*. 2012;126(3):261–269.
27. Greenwald JL, Halasyamani L, Greene J, et al. Making inpatient medication reconciliation patient centered, clinically relevant and implementable: a consensus statement on key principles and necessary first steps. *J Hosp Med*. 2010;5(8):477–485.
28. Castanheira L, Fresco P, Macedo AF. Guidelines for the management of chronic medication in the perioperative period: systematic review and formal consensus. *J Clin Pharm Therap*. 2011;36(4):446–467.
29. Hoeks SE, Scholte Op Reimer WJ, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. *Eur J Vasc Endovasc Surg*. 2007;33(1):13–19.
30. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. *Anesth Analg*. 2007;104(6):1326–1333.
31. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. *Am J Cardiol*. 2007;100(2):316–320.
32. Vaur L, Bobrie G, Dutrey-Dupagne C, et al. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. *Am J Hypertens*. 1998;11(2):165–173.
33. Piccoli GB, Anania P, Biancone L, et al. Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure. *Nephrol Dial Trans*. 2001;16(5):1084–1085.
34. Enseleit F, Hurlimann D, Luscher TF. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. *J Cardiovasc Pharmacol*. 2001;37(suppl 1):S21–S30.
35. Nonoguchi H, Kiyama S, Inoue H, et al. Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism. *Clin Nephrol*. 2003;60(4):225–232.
36. Smith MW, Joseph GJ. Pharmacy data in the VA health care system. *Med Care Res Rev*. 2003;60(3 suppl):92S–123S.
37. Szeto HC, Coleman RK, Gholami P, Hoffman BB, Goldstein MK. Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. *Am J Manag Care*. 2002;8(1):37–43.
38. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. *Am J Epidemiol*. 1995;141(3):242–250.
39. Lachin JM. Statistical considerations in the intent-to-treat principle. *Control Clin Trials*. 2000;21(3):167–189.
40. Sun JZ, Cao LH, Liu H. ACE inhibitors in cardiac surgery: current studies and controversies. *Hypertens Res*. 2010;34(1):15–22.